CyPass Glaucoma Micro-Stent Recall Issued Over Safety Concerns
Due to concerns that Alcon’s CyPass Glaucoma Micro-Stent may cause damage to a person’s eye, surgeons are being advised to stop using the device during glaucoma surgery.
The FDA announced a Alcon CyPass Micro-Stent recall August 29, indicating that safety data from a long-term follow up study found that the device poses an unreasonable risk.
The CyPass Micro-Stent is a device implanted in a person’s eye during glaucoma surgery, to help lower eye pressure and prevent the progression of glaucoma; however, it can pose other complications.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
The recall is global, affecting all micro-stent devices currently on the market.
The decision was made based on five-year followup data from the COMPASS-XT long-term safety study, which indicated that the stent may cause damage to the endothelial cells of the eye.
The FDA approved the CyPass Micro-Stent in July 2016, for use along with cataract surgery in patients with mild-to-moderate primary open-angle glaucoma. The approval came from the results of a two-year COMPASS-XT study.
The Compass-XT study was designed to collect safety data on participants who had the CyPass Micro-Stent implanted for an additional three years past the initial two year.
The results of the study showed a significant reduction in intraocular pressure at the two year post-surgery mark among patients who had the CyPass Micro-Stent implanted during cataract surgery, compared to those who only had cataract surgery completed.
Research indicated that at the two-year post-op mark, the patients who had the CyPass Micro-Stent and the patients who had only cataract surgery had similar low rates of endothelial cell loss, or eye damage. Based on the early two-year results, the FDA approved the Micro-Stent. However, by the five year post-op mark researchers found significant endothelial cell loss among the CyPass Micro-Stent group compared to cataract surgery patients. The endothelial loss could lead to further damage to the eye or vision loss.
For that reason, Alcon initiated the market withdrawal for all versions of CyPass Micro-Stent. Alcon has indicated it will contact surgeons to give recommendations on how to evaluate and manage the patients who have already received CyPass Micro-Stent surgery.
Alcon is also warning ophthalmic surgeons to stop CyPass Micro-Stent implantations immediately and return unused devices to the company.
“We believe that withdrawing the CyPass Micro-Stent from the market is in patients’ best interest and is the right thing to do,” said Dr. Stephen Lane, Chief Medical Officer at Alcon. “Although we are removing the product from the market now out of an abundance of caution, we intend to partner with the FDA and other regulators to explore labeling changes that would support the reintroduction of the CyPass Micro-Stent in the future.”
Patients who experienced side effects or vision problems following the implantation of the CyPass Micro-Stent should notify their doctor immediately. They should also contact the FDA MedWatch reporting program to report side effects.
PattsySeptember 26, 2018 at 7:45 pm
I also had cypass surgery in both eyes in Dec. 2017 and also in Jan 2018. I went to the doctor that performed the surgery and he informed me about the recall. I asked him if he could take them out, according to him, it would cause my pressure to soar. I feel between a rock and a hard place.What do I do now?????
MarenSeptember 5, 2018 at 2:29 am
I have had adverse effects from the Alcon micro-stent surgery since day 1 in July 2018. Because it never felt right even after a week, I decided to cancel the same surgery on my right eye. My doctor called me today to tell me the news about Alcon's recall. He told me to see my eye doctor regularly to monitor my eye health. Too late now!
"*" indicates required fields
More Top Stories
A ProPublica report reveals that Philips officials hid thousands of reports of problems with sound abatement foam used in millions of CPAP machines, failing to recall the devices for more than a decade after receiving the first complaints.
A Suboxone lawsuit claims the opioid addiction treatment's dental side effects can lead to severe tooth damage and decay.
The FDA is requiring new label warnings to alert patients and doctors to the risk of Ozempic intestinal blockage side effects.